Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Biocartis Group NV
  6. News
  7. Most relevant
    BCART   BE0974281132

BIOCARTIS GROUP NV

(BCART)
  Report
Real-time Euronext Bruxelles  -  11:35 2022-06-24 am EDT
2.095 EUR   +2.20%
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tagrisso
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for the Development and Marketing of a Companion Diagnostic Test for Tagrisso®
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BIOCARTIS GROUP NV
06/22ADRs End Lower; ArcelorMittal, AstraZeneca Trade Actively
DJ
06/22Biocartis, AstraZeneca To Jointly Develop Companion Lung Cancer Diagnostic Test For Tag..
MT
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for ..
GL
06/22PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces New Agreement with AstraZeneca for ..
AQ
06/22Biocartis Group NV Announces New Agreement with Astrazeneca for the Development and Mar..
CI
06/20Molecular Diagnostics Group Biocartis Introduces Lung Cancer Testing Panel
MT
06/20PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Launch of its Rapid CE-marked IVD I..
GL
06/20Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel ..
CI
06/20PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Launch of its Rapid CE-marked IVD I..
GL
06/15PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Reaches Key Commercial Milestones: One-Millio..
GL
06/15PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Reaches Key Commercial Milestones: One-Millio..
AQ
05/13PRESS RELEASE BIOCARTIS GROUP NV : Results of the Annual Shareholders' Meeting held on 13 ..
GL
05/04PRESS RELEASE BIOCARTIS GROUP NV : New Study Led by Memorial Sloan Kettering Cancer Center..
GL
05/04PRESS RELEASE BIOCARTIS GROUP NV : New Study Led by Memorial Sloan Kettering Cancer Center..
GL
05/04Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (N..
CI
04/25PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Presentation of Three Idylla™..
GL
04/25PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Presentation of Three Idylla™..
GL
04/21PRESS NEWS BIOCARTIS GROUP NV : Biocartis Announces Presentation of First Prospective Vali..
AQ
04/21PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Reports Results of First Quarter of 2022: On ..
AQ
04/21Biocartis Group NV Reconfirms Earnings Guidance of 2022
CI
04/12PRESS RELEASE BIOCARTIS GROUP NV : Invitation to the Annual Shareholders' Meeting
GL
03/31PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Publication of 2021 Annual Report
GL
02/24BIOCARTIS : Webcast presentation full year 2021 results
PU
02/24TRANSCRIPT : Biocartis Group NV, 2021 Earnings Call, Feb 24, 2022
CI
02/24BIOCARTIS : Announces 2021 results and 2022 outlook
PU
02/24PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces 2021 results and 2022 outlook
GL
02/24PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces 2021 results and 2022 outlook
GL
02/24Biocartis Group NV Provides Earnings Guidance for the Year 2022
CI
02/24Biocartis Group NV Reports Earnings Results for the Full Year Ended December 31, 2021
CI
02/17BIOCARTIS : Announces 2021 full year results on 24 february 2022
PU
02/17PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces 2021 full year results on 24 febru..
AQ
02/08Biocartis, Ophiomics to Jointly Commercialize Liver Cancer Test
MT
02/08PRESS RELEASE BIOCARTIS GROUP NV : Biocartis and Ophiomics to Collaborate on Liver Cancer..
AQ
02/08Biocartis and Ophiomics to Collaborate on Liver Cancer Test
CI
02/04PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
01/25Biocartis' Lung Cancer Test Shown to Improve Patient Survival Rates in UK Study
MT
01/25PRESS RELEASE BIOCARTIS GROUP NV : Large UK Study Shows Rapid EGFR Testing with Idylla&tra..
AQ
01/25Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in..
CI
01/10BIOCARTIS : Meets 2021 key objectives
PU
01/10PRESS RELEASE BIOCARTIS GROUP NV : Biocartis meets 2021 key objectives
AQ
2021Biocartis' COVID-19 Tests Found to Detect Omicron Variant
MT
2021PRESS RELEASE BIOCARTIS GROUP NV : Biocartis' Idylla™ SARS-CoV-2 testing Successfull..
AQ
2021Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant
CI
2021PRESS RELEASE BIOCARTIS GROUP NV : SeptiCyte® RAPID Receives 510(k) clearance by US FDA
AQ
2021Biocartis Group NV Announces SeptiCyte? Rapid Receives 510(K) Clearance by US FDA
CI
2021Biocartis' Epidermal Growth Factor Receptor Mutation Test Shows Reduced Patient Managem..
MT
2021PRESS RELEASE BIOCARTIS GROUP NV : New Study Demonstrates Idylla™ EGFR Mutation Test..
AQ
2021Biocartis Group NV Announces the Publication of New Study that Demonstrates That the Id..
CI
2021PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Q3 2021 Business Update
AQ
2021BIOCARTIS : Disclosure of a transparency notification
PU
2021PRESS NEWS BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
2021BIOCARTIS : Restarts Production Of ML2 Manufacturing Line
MT
2021BIOCARTIS : Announces Restart of its High-Throughput Cartridge Manufacturing Line
PU
2021PRESS RELEASE BIOCARTIS GROUP NV : Biocartis Announces Restart of its High-Throughput Cart..
AQ
2021Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Lin..
CI
2021BIOCARTIS : Disclosure of a transparency notification
PU
2021PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
2021BIOCARTIS : Webcast presentation H1 2021 results
PU
2021TRANSCRIPT : Biocartis Group NV, H1 2021 Earnings Call, Sep 02, 2021
CI
2021BIOCARTIS : Launches Idylla™ SARS-CoV-2/Flu/RSV Panel
PU
2021BIOCARTIS : announces H1 2021 results
PU
2021PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces H1 2021 results
AQ
2021Biocartis Group Nv Reports Earnings Results for the Half Year Ended June 30, 2021
CI
2021PRESS NEWS BIOCARTIS GROUP NV : Biocartis Launches Idylla™ SARS-CoV-2/Flu/RSV Panel
AQ
2021Biocartis Group NV Launches Idylla™ SARS-CoV-2/Flu/RSV Panel
CI
2021BIOCARTIS : Disclosure of a transparency notification
PU
2021PRESS RELEASE BIOCARTIS GROUP NV : Disclosure of a transparency notification
AQ
2021BIOCARTIS : Announces 2021 half-year results on 2 september 2021
PU
2021PRESS RELEASE BIOCARTIS GROUP NV : Biocartis announces 2021 half-year results on 2 septem..
AQ
2021PRESS RELEASE BIOCARTIS GROUP NV : Second Update on Fire Incident at Biocartis Warehouse
AQ
2021Biocartis Group NV Provides Update on Resumption of Production at ML2 line
CI
2021BIOCARTIS : Manufacturing Capacity Impaired Following Belgian Warehouse Fire
MT
2021BIOCARTIS : Update on Fire Incident at Biocartis Warehouse
PU
2021PRESS NEWS BIOCARTIS GROUP NV : Update on Fire Incident at Biocartis Warehouse
AQ
2021BIOCARTIS : Fire Incident at Biocartis Warehouse in Mechelen, Belgium
PU
1  2  3  4  5  6  7Next
Official Publications
05/13Proxy Statments 
05/13Proxy Statments 
04/211st quarter earnings 
04/211st quarter earnings 
04/12Mixed general shareholder meeting 
04/12Mixed general shareholder meeting 
Upcoming event on BIOCARTIS GROUP NV
09/01/22Interim 2022 Earnings Call
Upcoming sector events
07/19/22GETINGE AB : Interim 2022 Earnings Release
07/26/22MASIMO CORPORATION : Interim 2022 Earnings Release (Projected)
07/28/22NOVOCURE LIMITED : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Healthcare Services
 Healthcare Equipment & Supplies
  Medical Equipment, Supplies & Distribution
   Medical Equipment